Google
CGEN Stock Analysis — COMPUGEN (Healthcare >> Biotechnology)
CGEN FAQ
What is CGEN's P/E ratio?
COMPUGEN (CGEN) currently trades at a P/E ratio of 3.89.
What is CGEN's ROE?
COMPUGEN reports a Return on Equity (ROE) of 36.55%.
What is CGEN's dividend yield?
COMPUGEN offers a dividend yield of 0.00%.
What is CGEN's Quality Score?
Our AI rates CGEN's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CGEN?
Our AI Timing Score for CGEN is 94 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CGEN belong to?
COMPUGEN is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CGEN AI Analysis Summary
Our AI summary for CGEN: COMPUGEN (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.89, ROE of 36.55%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 94/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.35
Price
0.02
(0.64%)
Day Change
|
|
|---|
CGEN, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
63
GOOD
|
| Magic Formula Rank by ROE |
63
GOOD
|
| Magic Formula Rank by ROIC |
52
GOOD
|
| Price | 2.35 |
| PBV / Sector |
2.32 / 5.20
|
| Earning Per Share | 0.37 |
| PE / Sector |
3.89 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.03 / 1.22
|
| Average 1M Daily Value |
0.56 M
GREAT
|
| Average 1W Daily Value |
0.46 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:38 |
| Symbol | CGEN |
| Name | COMPUGEN |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 94.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 220.86 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Azrieli Center, Holon, Israel, 5885849
Phone: 972 3 765 8585
Website: https://cgen.com
Employees: 75
Sector: Healthcare >> Biotechnology
Description: Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer. Its preclinical therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and Gilead Sciences, Inc. for the research, development, manufacturing, and commercialization of COM503 and other products. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap